Science

CeMines approach is to improve the accuracy of cancer detection based on the cell’s regulatory mechanisms that are specifically related to cancer. The Company’s tests are based on unique alternative mRNA splice variants that are associated with specific cancers and on specific antibodies that are produced by the immune system in response to the different forms of cancer. Unlike competing products in the market, or under development, CeMines’ tests do not simply evaluate single biomarkers. Our tests analyze statistical relationships of multiple biomarkers that when combined, improve the accuracy of the testing results.